Maximizing ER-α Degradation Maximizes Activity in a Tamoxifen-Resistant Breast Cancer Model: Identification of GDC-0927-Reference-Cited by-同舟云学术

Maximizing ER-α Degradation Maximizes Activity in a Tamoxifen-Resistant Breast Cancer Model: Identification of GDC-0927

Published:2018-12-06 Issue:1 Volume:10 Page:50-55
ISSN:1948-5875
Container-title:ACS Medicinal Chemistry Letters
language:en
Short-container-title:ACS Med. Chem. Lett.

Author:

Kahraman Mehmet,Govek Steven P.,Nagasawa Johnny Y.,Lai Andiliy,Bonnefous Celine,Douglas Karensa,Sensintaffar John,Liu Nhin,Lee KyoungJin,Aparicio Anna,Kaufman Josh,Qian Jing,Shao Gang,Prudente Rene,Joseph James D.,Darimont Beatrice,Brigham Daniel,Heyman Richard,Rix Peter J.,Hager Jeffrey H.,Smith Nicholas D.^ORCID

Publisher

American Chemical Society (ACS)

Subject

Organic Chemistry,Drug Discovery,Biochemistry

Link

https://pubs.acs.org/doi/pdf/10.1021/acsmedchemlett.8b00414

Reference13 articles.

1. Estrogen Receptors: Therapies Targeted to Receptor Subtypes

2. Estrogen Receptors as Therapeutic Targets in Breast Cancer

3. Pathways to tamoxifen resistance

4. Biological determinants of endocrine resistance in breast cancer

5. Fulvestrant - A Novel Endocrine Therapy for Breast Cancer

Cited by 57 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Endocrine therapy for early breast cancer in the era of oral selective estrogen receptor degraders: challenges and future perspectives;Current Opinion in Oncology;2024-08-13

2. Selective Estrogen Receptor Degraders (SERDs);Current Breast Cancer Reports;2024-07-26

3. Oral SERDs alone or in combination with CDK 4/6 inhibitors in breast cancer: Current perspectives and clinical trials;The Breast;2024-06

4. A high-throughput platform for single-molecule tracking identifies drug interaction and cellular mechanisms;2024-05-13

5. Extensive Computational Studies for the Identification of Potential Therapeutic Candidates Against Breast Cancer;Current Indian Science;2024-03-19